Arpitha Komaragiri, MD
Clinical Neurophysiology · Shreveport, LANPI 1073975439
Payments from drug & device makers
Across 169 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$921
- DIXI Medical USA Corp$729
- Amgen$433
- UCB, Inc.$157
- Novartis$109
- EMD Serono, Inc.$106
- plus $650 from 15 others
What the payments were for
- Food & beverage$3,104100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 89 | $921 |
| DIXI Medical USA Corp | 1 | $729 |
| Amgen(2 entities) | 27 | $433 |
| UCB, Inc. | 7 | $157 |
| Novartis | 6 | $109 |
| EMD Serono, Inc. | 5 | $106 |
| Pfizer | 6 | $94 |
| Merz Pharmaceuticals, LLC | 3 | $80 |
| Acadia Pharmaceuticals Inc | 4 | $65 |
| AstraZeneca | 4 | $62 |
| Biogen | 2 | $50 |
| Amneal Pharmaceuticals LLC | 3 | $46 |
| Argenx US, Inc. | 2 | $42 |
| Impel Pharmaceuticals Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| TG Therapeutics, Inc. | 1 | $27 |
| Amylyx Pharmaceuticals, Inc. | 1 | $25 |
| Sanofi | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $14 |
How this compares
Too few clinical neurophysiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 88 | $1,694 |
| Levetiracetam ErLevetiracetam | 12 | $1,462 |
| Lacosamide | 16 | $1,195 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $417 |
| Zonisamide | 15 | $310 |
| Gabapentin | 19 | $228 |
| Lamotrigine | 14 | $95 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in Shreveport
- Fawad KhanNew Orleans$708K
- Cornel RogersGretna$13K
- James DomingueLafayette$2K
- Cheryl RinconKenner$557
- Jeffrey NichollNew Orleans$58
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.